The hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimate

Expert Rev Gastroenterol Hepatol. 2013 Jul;7(5):397-9. doi: 10.1586/17474124.2013.811050.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Carbamates
  • Enzyme Inhibitors / therapeutic use*
  • Half-Life
  • Hepacivirus / drug effects*
  • Hepacivirus / enzymology
  • Hepacivirus / growth & development
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / virology
  • Humans
  • Imidazoles / therapeutic use*
  • Models, Biological
  • Pyrrolidines
  • Time Factors
  • Treatment Outcome
  • Valine / analogs & derivatives
  • Viral Load
  • Viral Nonstructural Proteins / antagonists & inhibitors*
  • Viral Nonstructural Proteins / metabolism

Substances

  • Antiviral Agents
  • Carbamates
  • Enzyme Inhibitors
  • Imidazoles
  • Pyrrolidines
  • Viral Nonstructural Proteins
  • NS-5 protein, hepatitis C virus
  • Valine
  • daclatasvir